

Application No. 09/760.810  
Attorney's Docket No. 003300-737  
Page 2

CLAIM SUMMARY DOCUMENT

Claim 1. (Currently Amended) A method of treating a nerve disorder mediated by nucleus pulposus in a mammal in need of such treatment wherein said nerve disorder mediated by nucleus pulposus is caused by the liberation of TNF- $\alpha$  and compounds triggered by the liberation of or presence of TNF- $\alpha$  comprising the step of administering a TNF- $\alpha$  inhibitor, wherein said TNF- $\alpha$  inhibitor is a metalloproteinase inhibitor excluding methylprednisolone ~~for the treatment of nerve disorders mediated by nucleus pulposus in said to a mammal in need of such treatment wherein said nerve disorder mediated by nucleus pulposus is caused by the liberation of TNF- $\alpha$  and compounds triggered by the liberation of or presence of TNF- $\alpha$  by~~ thereby inhibiting TNF- $\alpha$  and treating said disorder.

Claim 2. (Canceled)

8 Claim ~~3~~. (Previously Added) The method of claim 1, wherein said nerve disorder is a nerve root injury.

Claim 4. (Canceled)

15 Claim ~~5~~. (Currently Amended) The method of claim ~~3~~ 1, wherein said nerve root injury ~~is nerve disorder presents as~~ sciatica.

2 Claim ~~6~~. (Previously Added) The method of claim 1, wherein the mammal is human.

9 Claim ~~7~~. (Previously Added) The method of claim ~~3~~ 8, wherein the mammal is human.

Application No. 09/760,810  
Attorney's Docket No. 003300-737  
Page 3

Claim 8. (Canceled)

16 Claim ~~9~~. (Previously Added) The method of claim ~~8~~<sup>15</sup>, wherein the mammal is human.

3 Claim ~~10~~. (Previously Added) The method of claim 1, wherein the TNF- $\alpha$  inhibitor is administered systemically.

10 Claim ~~11~~. (Previously Added) The method of claim ~~8~~<sup>8</sup>, wherein the TNF- $\alpha$  inhibitor is administered systemically.

Claim 12. (Canceled)

17 Claim ~~13~~. (Previously Added) The method of claim ~~8~~<sup>15</sup>, wherein the TNF- $\alpha$  inhibitor is administered systemically.

E1  
Cont  
4 Claim ~~14~~. (Previously Added) The method of claim 1, wherein the TNF- $\alpha$  inhibitor is administered orally.

11 Claim ~~15~~. (Previously Added) The method of claim ~~8~~<sup>8</sup>, wherein the TNF- $\alpha$  inhibitor is administered orally.

Claim 16. (Canceled)

18 Claim ~~17~~. (Previously Added) The method of claim ~~8~~<sup>15</sup>, wherein the TNF- $\alpha$  inhibitor is administered orally.

Application No. 09/760,810  
Attorney's Docket No. 003300-737  
Page 4

<sup>5</sup> Claim ~~18~~. (Previously Added) The method of claim 1, wherein the TNF- $\alpha$  inhibitor is administered intramuscularly.

<sup>8</sup>  
~~18~~ Claim ~~19~~. (Previously Added) The method of claim ~~8~~, wherein the TNF- $\alpha$  inhibitor is administered intramuscularly.

Claim 20. (Canceled)

<sup>15</sup>  
~~19~~ Claim ~~21~~. (Previously Added) The method of claim ~~8~~, wherein the TNF- $\alpha$  inhibitor is administered intramuscularly.

<sup>6</sup> Claim ~~22~~. (Previously Added) The method of claim 1, wherein the TNF- $\alpha$  inhibitor is administered intravenously.

<sup>8</sup>  
<sup>E1</sup>  
<sup>Cont</sup>  
~~13~~ Claim ~~23~~. (Previously Added) The method of claim ~~8~~, wherein the TNF- $\alpha$  inhibitor is administered intravenously.

Claim 24. (Canceled)

<sup>15</sup>  
~~20~~ Claim ~~25~~. (Previously Added) The method of claim ~~8~~, wherein the TNF- $\alpha$  inhibitor is administered intravenously.

Claims 26-48. (Canceled)

~~21~~ Claim ~~49~~. (New) The method of claim 1, wherein said nerve disorder is caused by a herniated disc.

Application No. 09/760.810  
Attorney's Docket No. 003300-737  
Page 5

<sup>21</sup>  
~~23~~ Claim ~~50~~. (New) The method of claim ~~49~~, wherein the TNF- $\alpha$  inhibitor is administered intravenously.

<sup>21</sup>  
~~23~~ Claim ~~51~~. (New) The method of claim ~~49~~, wherein the TNF- $\alpha$  inhibitor is administered systemically.

<sup>21</sup>  
~~24~~ Claim ~~52~~. (New) The method of claim ~~49~~, wherein the TNF- $\alpha$  inhibitor is administered orally.

<sup>21</sup>  
~~26~~ Claim ~~53~~. (New) The method of claim ~~49~~, wherein the mammal is human.

<sup>21</sup>  
~~26~~ Claim ~~54~~. (New) The method of claim ~~49~~, wherein the TNF- $\alpha$  inhibitor is administered intramuscularly.

E  
Cont  
<sup>7</sup> ~~27~~ Claim ~~55~~. (New) The method of claim 1, wherein said nerve disorder involves pain.

<sup>8</sup>  
<sup>14</sup> ~~27~~ Claim ~~56~~. (New) The method of claim ~~1~~, wherein said nerve disorder involves pain.

<sup>21</sup>  
<sup>27</sup> Claim ~~57~~. (New) The method of claim ~~49~~, wherein said nerve disorder involves pain.

---